Objective To summarize the current status and hotspots of research on obesity and neuroinflammation in the last decade through bibliometric analysis. Method Web of Science database was searched for English literature on obesity and neuroinflammation published between 2011 and 2021. The CiteSpace software was applied to analyze the number of publications, authors, institutions, countries and collaborations, and keywords in the field of obesity and neuroinflammation research.Results A total of 548 articles were included, and the number of articles had been increasing year by year. The top three countries in the field of obesity and neuroinflammation research were the United States, China, and Brazil. University of Toronto was the core research institution. Keywords formed 16 clusters, and there were a total of 15 emergent words.Conclusions Over the past decade, research on obesity and neuroinflammation has shown an upward trend. The research hotspots in the field of obesity and neuroinflammation mainly focus on insulin resistance, obesity, Alzheimer’s disease, high fat diet, inflammation, neuroinflammation, and other aspects. The prefrontal cortex and memory impairment are future hotspots.
Epilepsy is one of the most common neurological disorders, and status epilepticus (SE) can lead to permanent neuronal brain damage in the central nervous system, but the mechanism is not clear. Solving this problem will help to find more SE therapeutic targets, benefiting tens of millions of epilepsy patients. The pathway of SE leading to neuronal damage in the brain has made new progress in neuroinflammation, autophagy, apoptosis and pyroptosis, glial cell hyperplasia and category transformation, and changes in neurotransmitters in the brain, which will be beneficial to the discovery of new targets for the treatment of SE, thus laying a foundation for the development of new anti-epileptic drugs.
Currently, approximately one-third of epilepsy patients exhibit resistance to anti-seizure medications (Anti-seizure medications, ASMs), which can only alleviate symptoms, but cannot completely cure the condition. Consequently, the development of new ASMs from an understanding of epilepsy pathogenesis has emerged as an urgent social issue. The role of neuroinflammation in various neurological diseases has garnered significant attention as a popular research topic both domestically and internationally. Numerous studies have corroborated the involvement of neuroinflammation in the onset and progression of epilepsy. The biological target, Translocator protein 18 kDa (TSPO), is considered as a marker of neuroinflammation and is intricately involved in the entire neuroinflammatory response. Investigating the function of TSPO in epilepsy neuroinflammation can potentially uncover new treatment targets. At present, the exact mechanism of TSPO in epilepsy neuroinflammation remains unclear, thus necessitating a comprehensive summary and overview. This article reviewed the advancements made in TSPO research within the realm of neuroinflammation and its role in epileptic neuroinflammation, aiming to contribute novel insights for the identification of related targets and pathways for epilepsy treatment.